Suven's first clinical compound passes Phase I
This article was originally published in Scrip
Executive Summary
Suven Life Sciences of India has reported promising results from a Swiss Phase I study of its central nervous system (CNS) compound SUVN-502. This is the first of Suven's NCEs to enter clinic trials from its pipeline of six products.